Voglibose Tablets 0.2mg 15’s/blister Oral Medications

Voglibose Tablets 0.2mg 15’s/blister Oral Medications

Product : Voglibose Tablets

Specification : 0.2mg

Standard : In - house

Packing : 15’s/blister

Description :

Voglibose belongs to category of inositol drugs. Voglibose is a type of hypoglycemic agents.

Voglibose inhibits the hydrolase (alpha gluosidase) enzyme for disaccharides that catalyzes decoposition of disaccharides into monosaccharides in the intestine. Thereby, it delays the digestion and absorption of carbohydrate, resulting in improvement of postprandial hyperglycemia.

Indications and Usage :

Voglibose is indicated for improvement of postprandial hyperglycemia in diabetes mellitus only when diet and/or exercise or oral hyperglycemic drug or Insulin preparation in addition to diet and/or exercise, does not result in adequate glycemic (Glycemic) control. The avoidance of high postprandial (aftermeals) blood glucose level is one of the main advantages of drug.

Pharmacodynamics

Voglibose, an alpha-glucosidase inhibitor, is a synthetic compound with potent and enduring therapeutic efficacies against disorders of sensory, motor and autonomic nerve systems due to diabetes mellitus. The drug was approved in Japan in 1994 for the treatment of diabetes, and it is under further investigation by Takeda for the treatment of impaired glucose tolerance. Alpha-glucosidase inhibitors are oral anti-diabetic drugs used for diabetes mellitus type 2 that work by preventing the digestion of complex carbohydrates (such as starch). Complex carbohydrates are normally converted into simple sugars (monosaccharides) which can be absorbed through the intestine. Hence, alpha-glucosidase inhibitors reduce the impact of complex carbohydrates on blood sugar.

Mechanism of action

Alpha-glucosidase inhibitors are saccharides that act as competitive inhibitors of enzymes needed to digest carbohydrates: specifically alpha-glucosidase enzymes in the brush border of the small intestines. The membrane-bound intestinal alpha-glucosidases hydrolyze oligosaccharides, trisaccharides, and disaccharides to glucose and other monosaccharides in the small intestine. Acarbose also blocks pancreatic alpha-amylase in addition to inhibiting membrane-bound alpha-glucosidases. Pancreatic alpha-amylase hydrolyzes complex starches to oligosaccharides in the lumen of the small intestine. Inhibition of these enzyme systems reduces the rate of digestion of complex carbohydrates. Less glucose is absorbed because the carbohydrates are not broken down into glucose molecules. In diabetic patients, the short-term effect of these drugs therapies is to decrease current blood glucose levels: the long term effect is a small reduction in hemoglobin-A1c level.